Home » Rare Disease » WHATNEXT: Patients Aged 80 to 90 Respond to Standard-of-Care AML Treatment
WHATNEXT: Patients Aged 80 to 90 Respond to Standard-of-Care AML Treatment
Rose Duesterwald
Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.
All Posts